Critical Care Therapeutics in Major Developed Markets 2020

1. Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market (Type, Mode of action, Crop Type and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com Published on : Oct 2014

2. Report Overview ResearchBeam.com adds a report titled "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market". The report provides an in-depth study on the Critical Care Therapeutics in Major Developed Markets industry trends, opportunities and factors influencing the market. Summary GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

3. Report Overview The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. Get Full Details On: http://www.researchbeam.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the

4. Report Overview forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0% Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.The report includes - - A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns - Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals - A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period

5. Report Overview - Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets - Key drivers and restraints that have had and are expected to have a significant impact on the market - An overview of major licensing and co-development agreements that could affect growth trends Reasons to buy The report will enhance your decision-making capability by allowing you to - - Align your product portfolio to markets with high growth potential - Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth - Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market - Develop key strategic initiatives based on an understanding of key focus areas and leading companies - Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

6. Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Albumin in Critical Care 9 2.1.1 Overview 9 2.1.2 Diseases or Conditions Indicated for Albumin 9 2.1.3 Epidemiology 10 2.1.4 Other Treatment Options 10 2.1.5 Treatment Patterns 10 2.2 Anti-Thrombin III Concentrates in Critical Care 11 2.2.1 Overview 11 2.2.2 Anti-Thrombin Deficiencies 11 2.2.3 Epidemiology 11

7. Table of Contents 3 Therapeutic Landscape 19 3.1 Albumin Products 19 3.1.1 Buminate (albumin, human) - Baxter 19 3.1.2 Zenalb (human albumin) - Bio Products Laboratory 19 3.1.3 Human Albumin Biotest (albumin, human) - Biotest 19 3.1.4 AlbuRx (albumin) - CSL Behring 19 3.1.5 Albuminar (albumin, human) 5% - CSL Behring 20 3.1.6 Albutein (albumin (human)) - Grifols 204 Pipeline for Critical Care Market 29 4.1 Overview of Pipeline 29 4.2 Promising Pipeline Candidates 30 4.2.1 Octaplex 500 (human prothrombin complex) - Octapharma 30 4.2.2 KW-3357– Kyowa Hakko Kirin 30 4.2.3 Human AT Concentrate - Grifols 30

8. Table of Contents 5 Critical Care Market Forecast to 2020 31 5.1 Geographical Markets 31 5.1.1 Major Developed Markets 31 5.1.2 US 34 5.1.3 Top Five European Countries 36 5.1.4 Japan 40 5.1.5 Canada 42 5.2 Drivers and Barriers 44 5.2.1 Drivers 44 5.2.2 Barriers 45 Enquire About Report: http://www.researchbeam.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market/enquire-about-report

9. List of Tables Table 1: Critical Care Market, Atryn, Development Timeline, 2007–2013 22 Table 2: Critical Care Market, Global, Pharmaceutical Pipeline, 2014 54 Table 3: Critical Care Market, Major Developed Markets, Market Forecast, 2013–2020 55 Table 4: Critical Care Market, Major Developed Markets, Albumin, Market Forecast, 2013–2020 55 Table 5: Critical Care Market, Major Developed Markets, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 55 Table 6: Critical Care Market, Major Developed Markets, FXIII Concentrates, Market Forecast, 2013–2020 55 Table 7: Critical Care Market, Major Developed Markets, Fibrinogen Concentrates, Market Forecast, 2013–2020 56 Table 8: Critical Care Market, Major Developed Markets, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 56 Table 9: Critical Care Market, US, Market Forecast, 2013–2020 56 Table 10: Critical Care Market, US, Albumin, Market Forecast, 2013–2020 56 Table 11: Critical Care Market, US, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 57

10. List of Tables Table 12: Critical Care Market, US, FXIII Concentrates, Market Forecast, 2013–2020 57 Table 13: Critical Care Market, US, Fibrinogen Concentrates, Market Forecast, 2013–2020 57 Table 14: Critical Care Market, US, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 57 Table 15: Critical Care Market, UK, Market Forecast, 2013–2020 58 Table 16: Critical Care Market, UK, Albumin, Market Forecast, 2013–2020 58 Table 17: Critical Care Market, UK, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 58 Table 18: Critical Care Market, UK, FXIII Concentrates, Market Forecast, 2013–2020 58 Table 19: Critical Care Market, UK, Fibrinogen Concentrates, Market Forecast, 2013–2020 59 Table 20: Critical Care Market, UK, Market Forecast, Prothrombin Complex Concentrates, 2013–2020 59 Request For Discount: http://www.researchbeam.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market/purchase-enquiry

11. List Of Figures Figure 1: Critical Care Market, Global, Overall Pipeline Analysis (%), 2013 29 Figure 2: Critical Care Market, Major Developed Markets, Treatment Use Patterns, 2013–2020 32 Figure 3: Critical Care Market, Major Developed Markets, Revenue ($bn), 2013–2020 33 Figure 4: Critical Care Market, US, Treatment Use Patterns, 2013–2020 34 Figure 5: Critical Care Market, US, Annual Cost of Therapy and Revenue, 2013–2020 35 Figure 6: Critical Care Market, Top Five European Countries, Treatment Use Patterns, 2013 and 2020 37 Figure 7: Critical Care Market, Top Five European Countries, Annual Cost of Therapy ($), 2013–2020 38 Figure 8: Critical Care Market, Top Five European Countries, Revenue ($m), 2013–2020 39 Figure 9: Critical Care Market, Japan, Treatment Use Patterns, 2013–2020 40 Figure 10: Critical Care Market, Japan, Annual Cost of Therapy and Revenue, 2013–2020 41 Figure 11: Critical Care Market, Canada, Treatment Use Patterns, 2013–2020 42 Figure 12: Critical Care Market, Canada, Annual Cost of Therapy and Revenue, 2013–2020 43 Figure 13: GBI Research Market Forecasting Model 71

12. Similar Market Studies • Published Reports • Neos Therapeutics, Inc. - Product Pipeline Review - 2014 • http://www.researchbeam.com/neos-therapeutics-inc-product-pipeline-review-2014-market • CureVac GmbH - Product Pipeline Review - 2014 • http://www.researchbeam.com/curevac-gmbh-product-pipeline-review-2014-market • arGEN-X BV - Product Pipeline Review - 2014 • http://www.researchbeam.com/argen-x-bv-product-pipeline-review-2014-market

13. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/ Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com